Company Overview and News

to your dashboard

Headline News

ImpediMed enrols first patient in chronic heart failure trial

ImpediMed (ASX:IPD) has enrolled the first patient in its initial chronic heart failure (CHF) trial using the company’s “SOZO” device.

Updater Inc to reveal material results

Updater Inc (ASX:IPD) has been granted a trading halt in its CHESS Depositary Interests by the ASX, with its shares placed in pre-open.

ImpediMed begins lymphoedema study using its health device

ImpediMed (ASX:IPD) has commenced enrolment in the first planned clinical study of its “SOZO” device for lymphoedema, a condition that causes swelling in the body's tissues.

ImpediMed Ltd and Mayo Clinic to progress body fluid monitoring technology

ImpediMed Ltd (ASX:IPD) is a leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies.

ImpediMed Limited Release: Vanderbilt University To Begin Testing Next Generation Device

2016-07-18 devicespace
BRISBANE, Australia and CARLSBAD, Calif., July 18, 2016 /PRNewswire/ -- ImpediMed Limited (ASX:IPD) announces that it is partnering with Vanderbilt University for a series of patient and clinician human factors testing for the company's next generation technology platform. Testing is expected to conclude by end of September 2016.

ImpediMed Limited Release: Medicare Proposes New Reimbursement Rates, L-Dex Increases

2016-07-12 devicespace
BRISBANE, Australia and CARLSBAD, Calif., July 12, 2016 /PRNewswire/ -- ImpediMed Limited (ASX:IPD) is pleased to announce today the Centers for Medicare and Medicaid Services (CMS) has published the proposed outpatient payment rates for CY2017.  This includes code 93702 for the company's L-Dex® procedure for the assessment of lymphedema.  

Becoming a substantial holder


Appendix 3B


Change in substantial holding


Appendix 3B


Notice under section 708A(5)(e)


ImpediMed completes A$75 million Private Placement

2016-03-22 prnewswire
CARLSBAD, Calif., March 22, 2016 /PRNewswire/ -- ImpediMed Limited (ASX: IPD), a global provider of medical technology to measure, monitor and manage fluid status in patients, announced the completion of its recent capital raising activity, raising a total of A$75.1 million before costs.